Item 5. Other Information
ITEM 5.
OTHER INFORMATION .
None
30
PART IV
ITEM 6.
EXHIBITS
The following exhibits are filed with this
registration statement.
Exhibit
No.
Exhibit Description
3.1
Certificate of Incorporation (incorporated by reference to Exhibit 2.1 of Form DOS filed with the SEC on August 19, 2016).
3.2
Amended and Restated Bylaws.
3.3
Certificate of Designation of Alzamend Neuro, Inc. Series A Convertible Preferred Stock, dated May 30, 2016 (incorporated by reference to Exhibit 2.3 of Form 1-A/A filed with the SEC on February 4, 2020).
31.1*
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a)
31.2*
Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a)
32.1**
Certification of Chief Executive and Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code
101.INS*
XBRL Instance Document. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*
Inline XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
*Filed herewith.
** This certification will not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.
31
SIGNATURES
Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
ALZAMEND NEURO, INC.
Date: September 13, 2021
By:
/s/ Stephan Jackman
Stephan Jackman
Chief Executive Officer (principal executive officer)
Date: September 13, 2021
By:
/s/ Lien T. Escalona
Lien T. Escalona
Chief Financial Officer (principal financial and accounting officer)
32
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.